Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, Australia.
J Pharmacol Exp Ther. 2011 Feb;336(2):540-50. doi: 10.1124/jpet.110.176362. Epub 2010 Nov 12.
The glucagon-like peptide 1 receptor (GLP-1R) is a promising target for the treatment of type II diabetes mellitus because of its role in metabolic homeostasis. In recent years, difficulties with peptide therapies have driven the search for small-molecule compounds to modulate the activity of this receptor. We recently identified quercetin, a naturally occurring flavonoid, as a probe-dependent, pathway-selective allosteric modulator of GLP-1R-mediated signaling. Using Chinese hamster ovary cells expressing the human GLP-1R, we have now extended this work to identify the structural requirements of flavonoids to modify GLP-1R binding and signaling (cAMP formation and intracellular Ca(2+) mobilization) of each of the GLP-1R endogenous agonists, as well as the clinically used exogenous peptide mimetic exendin-4. This study identified a chemical series of hydroxyl flavonols with the ability to selectively augment calcium (Ca(2+)) signaling in a peptide agonist-specific manner, with effects only on truncated GLP-1 peptides [GLP-1(7-36)NH(2) and GLP-1(7-37)] and exendin-4, but not on oxyntomodulin or full-length GLP-1 peptides [GLP-1(1-36)NH(2) and GLP-1(1-37)]. In addition, the 3-hydroxyl group on the flavone backbone (i.e., a flavonol) was essential for this activity, however insufficient on its own, to produce the allosteric effects. In contrast to hydroxyl flavonols, catechin had no effect on peptide-mediated Ca(2+) signaling but negatively modulated peptide-mediated cAMP formation in a probe-dependent manner. These data represent a detailed examination of the action of different flavonoids on peptide agonists at the GLP-1R and may aid in the development of future small molecule compounds targeted at this receptor.
胰高血糖素样肽 1 受体 (GLP-1R) 是治疗 2 型糖尿病的有前途的靶点,因为它在代谢稳态中发挥作用。近年来,由于肽疗法的困难,人们一直在寻找能够调节该受体活性的小分子化合物。我们最近发现,槲皮素是一种天然存在的类黄酮,是一种依赖探针的、途径选择性的 GLP-1R 介导信号的别构调节剂。使用表达人 GLP-1R 的中国仓鼠卵巢细胞,我们现在已经扩展了这项工作,以确定类黄酮的结构要求,以修饰每种 GLP-1R 内源性激动剂(GLP-1(7-36)NH2 和 GLP-1(7-37))和临床使用的外源性肽模拟物 exendin-4 的 GLP-1R 结合和信号转导(cAMP 形成和细胞内 Ca2+动员)。这项研究确定了一系列具有选择性增强肽激动剂特异性钙 (Ca2+) 信号能力的羟基黄酮醇化学系列,其作用仅对截断的 GLP-1 肽 [GLP-1(7-36)NH2 和 GLP-1(7-37)] 和 exendin-4 有效,但对 oxyntomodulin 或全长 GLP-1 肽 [GLP-1(1-36)NH2 和 GLP-1(1-37)] 无效。此外,黄酮骨架上的 3-羟基(即黄酮醇)对于这种活性是必不可少的,但仅凭自身不足以产生别构效应。与羟基黄酮醇相反,儿茶素对肽介导的 Ca2+信号没有影响,但以探针依赖的方式负调节肽介导的 cAMP 形成。这些数据代表了对不同类黄酮在 GLP-1R 上对肽激动剂作用的详细研究,可能有助于开发针对该受体的未来小分子化合物。